Prescription medicine

  • Imatinib

    Imatinib

    Antitumor agent. It is effective in chronic myeloid leukemia, acute lymphoblastic leukemia, inoperable and / or metastatic malignant tumor stromal gastrointestinal tract, systemic mastocytosis, dermatofibrosarcoma , HES / CEL, MDS / MPD.

  • Flustop

    Flustop

    Treatment of influenza in adults and children over the age of 12 years.

    Prevention of influenza in adults and adolescents over 12 years of age who are at high risk of infection with the virus (in military units and large production teams, in weakened patients).

     

  • Cinnarizine –NAN

    Cinnarizine –NAN

    Pharmacological effect- vasodilator, improving brain blood circulation, improving peripheral circulation. Cinnarizine intake is shown in the following diseases: vestibular disorders (including Meniere's disease, vertigo, tinnitus, nystagmus, nausea and vomiting of labyrinth origin). Prevention kinetoses ( " motion sickness" - sea and air sickness). Peripheral circulatory disorders (Charcot Syndrome, acrocyanosis, Raynaud's disease, cold extremities, diabetic angiopathy, thrombophlebitis, trophic disorders, including trophic and varicose ulcers). Chronic cerebrovascular insufficiency, including with residual problems after stroke (dizziness, tinnitus, headache, impaired memory and attention). Migraine Headache (prevention of attacks).

  • Pentoxifylline –NAN

    Pentoxifylline –NAN

    Pharmacotherapeutic group: peripheral vasodilator.

    Pentoxifylline treatment leads to improvement of symptoms disorders of cerebral circulation. The beneficial therapeutic results were observed in the case of pentoxifylline in vascular pathology of eyes and inner ear. Improves microcirculation in the areas of impaired blood supply. At peripheral arterial occlusive disease (Charcot Syndrome) leads to longer-distance walking, elimination of night leg cramps and pain at rest. Has a beneficial effect on tissue trophic disorders (including with venous ulcers).

  • Losartan

    Losartan

    Pharmacotherapeutic group: angiotensin receptor antagonist II. Losartan reduces the total peripheral vascular resistance, blood pressure, has a diuretic effect. Prevents the development of myocardial hypertrophy, increases exercise tolerance in patients with chronic heart failure.

  • Ursaklin

    Ursaklin

    Pharmacotherapeutic group: Drugs used in the treatment of diseases of the liver and biliary tract. Formulations of bile acids.

    Pharmacological effect - cholelitholytic, choleretic, hepatoprotective , cholesterol-lowering , immunomodulatory , etc.

  • HeptalNAN

    HeptalNAN

    Ademethionine is an amino acid that participates in the body in various metabolic processes.

    Indications for use

    The drug is indicated for the treatment of adults with:

    - intrahepatic cholestasis with precirrotic and cirrhotic conditions,

    Intrahepatic cholestasis during pregnancy;

    - symptoms of depression.

     

  • Pramipexol-NAN

    Pramipexol-NAN

    Pramipexole is a dopamine receptor agonist, with high selectivity and specificity, it binds to the dopamine receptors of subgroup D2, of which it has the most pronounced affinity for D3 receptors.

    Treatment of signs and symptoms of idiopathic Parkinson's disease in adults (as a monotherapy (without levodopa) or in combination with levodopa) during the course of the disease until later stages, when the effect of levodopa decreases or becomes unstable and the therapeutic effect ("on-off" phenomenon).

     

    Symptomatic treatment of idiopathic restless leg syndrome from moderate to severe in adults in doses of not more than 0.75 mg.

  • Candesartan

    Candesartan

    Candesartan-NAN contains the active substance candesartan cilexetil, which belongs to the group of angiotensin II receptor antagonists. This drug relaxes and dilates the blood vessels and, thus, helps lower blood pressure and facilitates the pumping work of the heart.

    Indications for use

    - treatment of arterial hypertension in adults;

    - treatment of hypertension in children and adolescents aged 6 to 18 years;

    - treatment of adult patients with heart failure and a violation of left ventricular systolic function (reduction of left ventricular ejection fraction ≤ 40%) as adjunctive therapy to angiotensin converting enzyme (ACE) inhibitors or intolerant of ACE inhibitors (see sections "Method of administration and dose "," Special instructions "," Interaction with other medicinal products "and" Pharmacological properties ").

  • Diadeon

    Diadeon

    Pharmacotherapeutic group: Oral hypoglycemic agents, excluding insulin. Sulfonamides, sulfonylureas

    Diadeon is an oral antidiabetic hypoglycemic drug that lowers blood glucose levels by stimulating insulin secretion.

  • Ranolazine- NAN

    Ranolazine- NAN

    Symptomatic treatment of adult patients with stable angina for additional therapy with insufficient therapeutic effect of basic therapy or intolerance of antianginal first-line drugs (such as beta-blockers and / or calcium antagonists).

  • Valsartan-NAN

    Valsartan-NAN

    Pharmacotherapeutic group: Angiotensin II receptor antagonist.

    Valsartan has an antihypertensive effect. When treating arterial hypertension, valsartan lowers blood pressure (BP), without affecting the heart rate (heart rate).

    Indications for use

    - arterial hypertension;

    - recently transferred myocardial infarction (treatment of clinically stable patients with clinical manifestations of heart failure or asymptomatic left ventricular systolic dysfunction after a 12-hour-10-day myocardial infarction);

    - Heart failure (treatment of heart failure with clinical symptoms, with the inability to use ACE inhibitors or as an additional therapy for ACE inhibitors when it is not possible to use beta-blockers).

  • Co-Valsartan

    Co-Valsartan

    Medicines  that affect the renin-angiotensin system.

    Angiotensin II antagonists and diuretics.

    The active substances of the drug are valsartan and hydrochlorothiazide.

    Indications for use

      Treatment of arterial hypertension in adult patients who do not manage to achieve adequate control of arterial pressure with monotherapy with valsartan or hydrochlorothiazide.

  • Losartan-NAN

    Losartan-NAN

    Pharmacotherapeutic group: Angiotensin II receptor antagonist.

    Reduces the overall peripheral resistance of blood vessels, reduces afterload, lowers blood pressure (BP). Reduces the pressure in the small (pulmonary) circle of blood circulation, prevents the delay of sodium and water in the body. Increases exercise tolerance in patients with heart failure.

  • Nicergolin-NAN

    Nicergolin-NAN

    Indications for use

    Symptomatic treatment of mild to moderate severe dementia for correction of cognitive and behavioral disorders.

  • Valsamlodin

    Valsamlodin

    Means that affect the renin-angiotensin system. Angiotensin II antagonists and calcium channel blockers.

    Indications for use. Arterial hypertension in patients in whom the level of arterial pressure is not controlled by amlodipine or valsartan monotherapy.